Ki67在肿瘤中的表达及其临床指导意义

The Expression and Clinical Significance of Ki67 in Tumor

近年来,研究表明ki67的表达与很多肿瘤疾病的发生发展密切相关,如乳腺癌、卵巢癌、淋巴癌等。临床上,常通过免疫组化的方法检测ki67指数,反映正常和病变组织或细胞的增殖活性,对良、恶性肿瘤进行鉴别诊断,帮助恶性肿瘤的早期诊断、治疗方法选择和疗效的评估。但是,目前在临床和基础研究中,均无法以一个固定的ki67值判定不同肿瘤疾病的恶性程度,也无法以一个精确的ki67临界值判定肿瘤的恶性程度,有时更需要在治疗过程中对病患肿瘤组织的ki67指标进行跟踪检查来指导新的治疗及判断预后。本文主要就目前ki67指数与不同肿瘤的恶性程度、治疗效果及预后判断的关系进行了综述。

In recent years, many studies have shown that Ki67 expression is closely related to the development of different kinds of tumors, such as breast cancer, ovarian cancer, lymphoma, etc. Clinically, Ki67 index is usually detected by immunohistochemical（IHC） to reflect the proliferative activity of normal and diseased tissue, which may help identify the benign and malignant disease. As a reference value, it guides a lot in the early diagnosis, treatment and evaluation of curative effect. But in clinical and basic research, there is no fixed threshold of Ki67 that can help determine the malignance; moreover, a precise Ki67 value is not enough to quantify the malignance of tumor. In some cases, the dynamic tracking for Ki67 is essential for optimizing treatment and prognosis. In this article, the correlations of Ki67 index with malignant grade, therapeutic effect and prognostic prediction of different kinds of tumors are reviewed.